Search results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a secondary subject of discussion.
May 2026
The rapid uptake of newer nicotine products, such as e-cigarettes and oral pouches, particularly among young people, threatens the slow progress over many years in tobacco control and poses substantial risks to cardiovascular health throughout the world. A December 2025 report in the European Heart Journal offers a policy blueprint to respond to the addictive and harmful effects of nicotine and “prevent the rise of a new generation of nicotine-addicted youth.”
November 2018
If you are a smoker, quitting is the most important thing you can do for your health. Learn why we recommend that varenicline only be used a last-resort drug for smoking cessation.
March 2015
In October 2014, Public Citizen joined four other consumer advocacy and research groups to petition the FDA to require stronger warnings on the label of the smoking cessation drug varenicline (CHANTIX). Learn about the drug’s severe psychiatric and neurological side effects that could potentially lead to fatal consequences.
September 2011
Find out why the FDA is now requiring patient warnings on this drug about an increased risk of cardiovascular adverse events in patients with existing cardiovascular disease. This adds to the growing list, including many psychiatric adverse effects, of problems associated with varenicline.
September 2007
Varenicline was approved by the FDA in May 2006 for use as an aid in smoking cessation treatment. It belongs to a new family of drugs, not containing nicotine, but thought to work by stimulating nicotine receptors in the brain, just as nicotine does.
Login
Subscribe